Department of Bionanotechnology, Gachon University, Incheon, Republic of Korea.
Research and Development, PeopleBio Inc., Gyeonggi-do, Republic of Korea.
Alzheimers Res Ther. 2017 Oct 17;9(1):86. doi: 10.1186/s13195-017-0310-6.
A reliable blood-based assay is required to properly diagnose and monitor Alzheimer's disease (AD). Many attempts have been made to develop such a diagnostic tool by measuring amyloid-β oligomers (AβOs) in the blood, but none have been successful in terms of method reliability. We present a multimer detection system (MDS), initially developed for the detection of prion oligomers in the blood, to detect AβOs.
To characterize Aβ in the blood, plasma was spiked with synthetic amyloid-β (Aβ) and incubated over time. Then, the MDS was used to monitor the dynamic changes of AβO levels in the plasma.
Increasing concentrations of AβOs were observed in the plasma of patients with AD but not in the plasma of normal control subjects. The plasma from patients with AD (n = 27) was differentiated from that of the age-matched normal control subjects (n = 144) with a sensitivity of 83.3% and a specificity of 90.0%.
Synthetic Aβ spiked into the blood plasma of patients with AD, but that of not elderly normal control subjects, induced dynamic changes in the formation of AβOs over time. AβOs were detected by the MDS, which is a useful blood-based assay with high sensitivity and specificity for AD diagnosis.
需要一种可靠的基于血液的检测方法来正确诊断和监测阿尔茨海默病（AD）。许多人试图通过测量血液中的淀粉样β寡聚物（AβOs）来开发这种诊断工具，但在方法可靠性方面均未成功。我们提出了一种多聚体检测系统（MDS），最初用于检测血液中的朊病毒寡聚物，以检测 AβOs。
为了研究血液中的 Aβ，将合成的淀粉样β（Aβ）加入到血浆中，并随时间孵育。然后，使用 MDS 监测血浆中 AβO 水平的动态变化。
在 AD 患者的血浆中观察到 AβOs 的浓度逐渐增加，但在正常对照者的血浆中未观察到。AD 患者（n=27）的血浆与年龄匹配的正常对照者（n=144）区分开来，其灵敏度为 83.3%，特异性为 90.0%。
在 AD 患者的血浆中加入合成的 Aβ，但不会在老年正常对照者的血浆中加入，诱导 AβOs 的形成随时间发生动态变化。MDS 可检测到 AβOs，这是一种具有高灵敏度和特异性的用于 AD 诊断的有用的基于血液的检测方法。
